At Aegros we believe access to life saving therapeutic plasma drugs is a human right and not a privilege.
Our mission is to put the patient first through innovation and we do this thanks to our Australian invented Haemafrac®, Aegros' unique electroseparation process.
Our TGA GMP-approved plasma fractionation plant in Macquarie Park, Sydney, manufactures a hyperimmune immunoglobulin product against Covid-19, made from convalescent plasma.
Aegros is currently undertaking the final preparations for the submission of a dossier for the registration of this hyperimmune against Covid-19 on the Australian Register of Therapeutic Goods (ARTG)
Simultaneously, Aegros is finishing the upgrade of its existing hyperimmune facility at Macquarie Park NSW to be able to process 100,000l of plasma per year.
Company Details
- Employees
- 65
- Founded
- -
- Address
- 5 Eden Park Drive, Macquarie Park,nsw 2113,australia
- Phone
- +61 29-856-3500
- in****@****.com.au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- aegros.com.au
- HQ
- Macquarie Park, NSW
Aegros Questions
Aegros's helpline number is +61 29-856-3500
Aegros's website is aegros.com.au
Aegros's LinkedIn profile is https://au.linkedin.com/company/aegros
Aegros has
65 employees.
View email and phone details for 65
employees at Aegros.
Aegros's industry is
Biotechnology Research
Aegros's top competitors are
Inventia Life Science,
Sequins,
Astrazeneca,
Virbac,
Ausbiotech,
Vvmf - Viral Vector Manufacturing Facility,
Csl,
Regeneus Ltd,
Tissuelabs,
Vow.
Aegros's support email address is info@aegros.com.au
Aegros's categories are Biotechnology Research
Aegros's founding year is 2017
